Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Koji Tanikawa"'
Autor:
Masaru Samura, Keisuke Takada, Naoki Hirose, Takenori Kurata, Fumio Nagumo, Masaki Uchida, Junki Inoue, Koji Tanikawa, Yuki Enoki, Kazuaki Taguchi, Kazuaki Matsumoto, Takashi Ueda, Shigeru Fujimura, Hiroshige Mikamo, Yoshio Takesue, Kotaro Mitsutake
Publikováno v:
British Journal of Clinical Pharmacology. 89:1291-1303
Autor:
Keisuke Takada, Mitsuchika Nakamura, Masaru Samura, Junki Inoue, Naoki Hirose, Takenori Kurata, Humio Nagumo, Junichi Ishii, Sakura Koshioka, Koji Tanikawa, Hiroyuki Kunishima
Publikováno v:
YAKUGAKU ZASSHI. 142:189-193
Autor:
Koji Tanikawa, Takenori Kurata, Fumio Nagumo, Yuki Enoki, Ryuji Higashita, Kazuaki Matsumoto, Kazuaki Taguchi, Sakura Koshioka, Norifumi Kunika, Masaru Samura, Masaki Uchida, Keisuke Takada, Hayato Ito, Risako Yamamoto
Publikováno v:
Pharmaceutical Research. 38:1041-1055
This study evaluated the population pharmacokinetics of daptomycin in nonobese elderly patients with hypoalbuminemia and chronic kidney disease (CKD) using the glomerular filtration rate estimated from cystatin C (eGFRcys) and estimated its optimal d
Autor:
Keisuke, Takada, Yukiyoshi, Sada, Masaru, Samura, Masashi, Matsuura, Naoki, Hirose, Takenori, Kurata, Fumio, Nagumo, Junichi, Ishii, Sakura, Koshioka, Masaki, Uchida, Junki, Inoue, Koji, Tanikawa, Hiroyuki, Kunishima
Publikováno v:
American Journal of Case Reports. 23
BACKGROUND Rhabdomyolysis is a condition in which intracellular components are released into the blood and urine. Rhabdomyolysis can be caused by drug-related complications and COVID-19; however, the underlying mechanism is not clear. In this study,
Autor:
Masaru Samura, Keisuke Takada, Naoki Hirose, Takenori Kurata, Fumio Nagumo, Sakura Koshioka, Junichi Ishii, Masaki Uchida, Junki Inoue, Yuki Enoki, Kazuaki Taguchi, Koji Tanikawa, Kazuaki Matsumoto
Publikováno v:
British journal of clinical pharmacologyREFERENCES. 88(5)
The present systematic review and meta-analysis evaluated the incidence of elevated creatine phosphokinase (CPK) levels between daptomycin alone and concomitant daptomycin and statin use.We searched the PubMed, Web of Sciences, Cochrane Library and C
Autor:
Junki Inoue, Koji Tanikawa, Masaki Uchida, Ryuji Higashita, Yuki Enoki, Keisuke Takada, Junichi Ishii, Fumio Nagumo, Kazuaki Taguchi, Sakura Koshioka, Naoki Hirose, Masaru Samura, Norifumi Kunika, Takenori Kurata, Kazuaki Matsumoto
Publikováno v:
Open Forum Infectious Diseases
Background In this study, we investigated the risk factors for daptomycin-associated creatine phosphokinase (CPK) elevation and established a risk score for CPK elevation. Methods Patients who received daptomycin at our hospital were classified into
Autor:
Kazunori Matsuda, Yuta Kimura, Kohei Miwa, Hiroshi Kajiyama, Koji Tanikawa, Atsushi Maeda, Aimi Ueda, Masaki Takeda, Ayano Yonemura
Publikováno v:
Journal of Smart Processing. 9:122-125
Autor:
Hiroo Nakashima, Junji Saruwatari, Takateru Ishitsu, Masatsugu Shimomasuda, Sunao Kaneko, Miki Nishimura, Yoshiyuki Tsuda, Norio Yasui-Furukori, Takayuki Seo, Rie Nagata, Koji Tanikawa, Kazuko Nakagawa, Naoki Ogusu
Publikováno v:
Therapeutic Drug Monitoring. 36:302-309
Clobazam (CLB) is a 1,5-benzodiazepine with antiepileptic properties. More than 70% of administered CLB is dealkylated to yield N-desmethylclobazam (N-CLB), a pharmacologically active metabolite, by cytochrome P450 (CYP) 3A4 and CYP2C19. The subseque
Autor:
Makiko Shimizu, Takashi Matsuzaki, Koji Tanikawa, Masamichi Fukuoka, Yoshiaki Matsumoto, Mitsuo Matsumoto
Publikováno v:
Biological and Pharmaceutical Bulletin. 23:235-239
A computer program is described for maximum likelihood estimation within the gamma or normal distribution which can be used to estimate pharmacokinetic parameters. Pharmacokinetic analysis using this proposed program was investigated by the Monte Car
Autor:
Kazutoyo Endo, Rie Yamamoto, Tsugio Sawachi, Koji Tanikawa, Toshio Nakamura, Masamichi Fukuoka, Mitsuo Matsumoto, Yoshiaki Matsumoto
Publikováno v:
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 29:489-494
A population pharmacokinetic analysis of valproic acid in conventional and slow release formulations was carried out. Three hundred and forty-four points in two hundred and fifteen patients were analyzed. The pharmacokinetic model, which took into ac